Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes
| Autor: | Carlo Cenciarelli, Giuseppe Sconocchia, Giulia Lanzilli, Thomas Caceci, Roberto Arriga, Hany E. Marei, Asma Althani, Alessio Ottaviani, Mario Roselli, Tommaso Sconocchia, Sara Caratelli |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Fcgamma-CR T cell CAR T cells Fcγ-CR T cell Hematological malignancies Immunotherapy Solid cancers Settore MED/09 - Medicina Interna Settore MED/06 - Oncologia Medica medicine.medical_treatment T cell Cell Biochemistry Immunotherapy Adoptive Cell therapy 03 medical and health sciences Therapeutic approach 0302 clinical medicine Antigen Neoplasms medicine Animals Humans Receptor Pharmacology Receptors Chimeric Antigen business.industry Receptors IgG Chimeric antigen receptor 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Cancer research business |
| Zdroj: | Biochemical pharmacology 166 (2019): 335–346. doi:10.1016/j.bcp.2019.06.002 info:cnr-pdr/source/autori:Hany E. Marei 1, Asma Althani 2, Thomas Caceci 3, Roberto Arriga 4, Tommaso Sconocchia 5, Alessio Ottaviani 6, Giulia Lanzilli 6, Mario Roselli 4, Sara Caratelli 6, Carlo Cenciarelli 6*, Giuseppe Sconocchia 6*/titolo:Recent perspective on CAR and Fcgamma-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes/doi:10.1016%2Fj.bcp.2019.06.002/rivista:Biochemical pharmacology/anno:2019/pagina_da:335/pagina_a:346/intervallo_pagine:335–346/volume:166 |
| ISSN: | 1873-2968 |
| DOI: | 10.1016/j.bcp.2019.06.002 |
| Popis: | The chimeric antigen receptor T cell (CAR-T cell) immunotherapy currently represents a hot research trend and it is expected to revolutionize the field of cancer therapy. Promising outcomes have been achieved using CAR-T cell therapy for haematological malignancies. Despite encouraging results, several challenges still pose eminent hurdles before being fully recognized. Directing CAR-T cells to target a single tumour associated antigen (TAA) as the case in haematological malignancies might be much simpler than targeting the extensive inhibitory microenvironments associated with solid tumours. This review focuses on the basic principles involved in development of CAR-T cells, emphasizing the differences between humoral IgG, T-cell receptors, CAR and Fcgamma-CR constructs. It also highlights the complex inhibitory network that is usually associated with solid tumours, and tackles recent advances in the clinical studies that have provided great hope for the future use of CAR-T cell immunotherapy. While current Fcgamma-CR T cell immunotherapy is in pre-clinical stage, is expected to provide a sound therapeutic approach to add to existing classical chemo- and radio-therapeutic modalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect